Skip to Main Content

Paper Details

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Oncologist
34
2021
CD8, DNA mismatch repair-deficient (dMMR) prostate cancer, ICI, Mismatch Repair-Deficient Prostate Cancer, PD1, PSA50, Patient, advanced prostate cancer, anti-PD1, dMMR, dMMR cancers, men, metastatic castration-resistant prostate cancer, nonprostatic, nonprostatic dMMR cancers, patients, prostate cancer, tumor, tumor-infiltrating lymphocytes
Author NameAffiliation
Pedro Isaacsson VelhoThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Colin C PritchardUniversity of Washington
Alan H BryceMayo Clinic
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
Tamara L LotanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Emmanuel S AntonarakisThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Emmanuel S AntonarakisBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
  • 1 - 7

Datasets

Release 1.2